No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home FINTECH

Sectra acquires Oxipit, advancing autonomous AI capabilities in diagnostic imaging

Cisionby Cision
March 5, 2026
Reading Time: 4 mins read
in FINTECH, PRIVATE EQUITY, SCANDINAVIA&BALTICS
Share on FacebookShare on Twitter

LINKÖPING, Sweden, March 5, 2026 /PRNewswire/ — International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has entered into an agreement to acquire Oxipit, UAB, a Lithuanian company specializing in AI-based solutions for radiology. Oxipit holds the first CE Class IIB certification for autonomous AI in chest X-ray analysis. The transaction is subject to customary closing conditions and is expected to be completed during March 2026.

Most AI in radiology today acts as decision support, flagging findings, suggesting measurements, or assisting prioritization. These tools support radiologists but do not replace any part of the reporting process. Autonomous AI represents a different model. It is developed and validated to independently complete a specific diagnostic task under controlled clinical conditions. The scope of autonomy is clearly defined, performance thresholds are rigorously validated, and use is governed by regulatory approval.

Oxipit’s ChestLink is a leading example of this autonomous approach. Within its defined clinical scope, it is designed to automatically identify and clear high-confidence normal chest X-ray examinations from the radiologist’s worklist. This allows radiologists to focus their expertise on cases with a higher probability of disease. By safely reducing routine workload, this model directly addresses the growing challenge of rising imaging volumes and persistent workforce constraints, while operating under rigorously validated safety thresholds. ChestLink holds CE Class IIb certification*, reflecting the elevated regulatory and clinical validation standards required for autonomous AI applications in healthcare.

ChestLink is already available through Sectra Amplifier Marketplace for AI, supporting seamless integration into existing radiology workflows.

“The ability to autonomously clear high-confidence normal cases mark a transformative step for radiology. By combining clinical confidence with intelligent automation, we can expand capacity, reduce radiologist workload, and generate substantial financial benefits through higher productivity and lower cost. We look forward to continuing to sell Oxipit products in Europe and advancing the necessary regulatory approvals to bring it to more markets worldwide,” says Torbjörn Kronander, President and CEO of Sectra.

Oxipit was founded in 2017 and has developed a portfolio of CE-marked AI solutions for radiology spanning chest X-ray, CT, and musculoskeletal imaging. The solutions are currently deployed across multiple markets internationally.

The Oxipit team will operate as a dedicated AI development center within Sectra’s Imaging IT Solutions operating area. Alongside Sectra’s own capabilities, Sectra’s Amplifier service will remain an open, vendor-neutral ecosystem, providing healthcare providers access to AI applications from a wide range of vetted partners.

The acquisition will be financed using Sectra’s own funds and comprises an upfront cash consideration and an additional contingent consideration linked to commercial and regulatory milestones. Financial terms are not disclosed. The acquisition is not expected to have any material impact on the Sectra Group’s sales and operating profit for the current year.

Answers to frequently asked questions about the acquisition are available on our website>>.

* CE class IIb certification confirms compliance with EU medical device regulations and permits commercialization within the EEA.

Book a demo at ECR 2026
Visit Booth #D02 for a demonstration of Sectra’s AI offering including the CE Class IIB-certified ChestLink solution. See how autonomous AI optimizes radiology workflows while maintaining high safety standards. Read more about our highlights at ECR and book your demo! 

For further information, please contact: Dr. Torbjörn Kronander, CEO and President Sectra AB, 46 (0) 705 23 52 27
Marie Ekström Trägårdh, Executive Vice President Sectra AB and President Sectra Imaging IT Solutions, 46 (0)708 23 56 10

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/sectra/r/sectra-acquires-oxipit–advancing-autonomous-ai-capabilities-in-diagnostic-imaging,c4316312

The following files are available for download:

https://news.cision.com/sectra/i/radiologist-reading-lung-x-ray-in-sectra-s-solution,c3516585

Radiologist reading lung X-ray in Sectra’s solution

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/sectra-acquires-oxipit-advancing-autonomous-ai-capabilities-in-diagnostic-imaging-302705087.html

Read the orginal article: undefined

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

DACH

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm

March 5, 2026
GREEN

2MW data center being developed in central Finland, will be integrated into district heating

March 5, 2026
PRIVATE EQUITY

EYE NEWS UPDATE: Foxtons publishes full year financial results

March 5, 2026

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Italian private equity accelerates, driven by add-ons. BeBeez reports.

Italian private equity accelerates, driven by add-ons. BeBeez reports.

September 7, 2025
AlixPartners: Automotive, retail and manufacturing sectors may go through restructuring in 2025

AlixPartners: Automotive, retail and manufacturing sectors may go through restructuring in 2025

July 11, 2025
Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Next Post

Dragonfly-inspired DeepTech: Austria’s fibionic secures €3 million for its nature-inspired lightweight technology

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart